Hybridoma cell line G250 and its use for producing monoclonal antibodies
This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G 250 . Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G 250 as well as derivatives thereof such as chimeric and humanized G 250 antibodies.
1 . Hybridoma cell DSM ACC 2526 which produces the monoclonal antibody G250.
2 . Cell derived from hybridoma cell DSM ACC 2526 which produces a G250 antibody.
3 . The cell according to claim 2 which has been obtained by transfer of genetic material encoding antibody G250 or at least the antigen-binding site thereof into a receptor cell.
4 . The cell according to claim 2 which produces a chimeric antibody, a humanized antibody, a fully humanized antibody, a bispecific antibody, a single chain antibody, or F(ab′) 2 , Fab′, or Fab antibody fragments.
5 . The receptor cell according to claim 3 which is a prokaryotic cell.
6 . The cell according to claim 5 which is an E. coli cell.
7 . The cell of claim 3 which is a eukaryotic cell.
8 . The cell according to claim 7 which is a yeast cell, a myeloma cell or a CHO-cell.
9 . A method of producing a G250 antibody comprising:
cultivating a cell according to claim 1 under suitable conditions, wherein the antibody is produced and obtaining the antibody from the cell and/or from the culture medium.
10 . The method according to claim 8 used for producing a pharmaceutical formulation which comprises the G250 antibody as an active agent.
11 . The method according to claim 10 , wherein the pharmaceutical formulation comprises the chimeric G250 antibody.
12 . The method according to claim 10 , wherein the pharmaceutical formulation comprises the chimeric G250 antibody in radiolabeled form.
13 . The method according to claim 10 , wherein the pharmaceutical formulation comprises a chimeric G250 antibody coupled to a cytokine such as IL-2, TNF and/or GM-CSF.
14 . Use of a cell according to claim 1 for the manufacture of a G250 antibody.
15 . Use of a G250 antibody for the manufacture of an agent for eliciting a delayed immune response in cancer therapy.
16 . The use of claim 15 in the treatment of renal cell carcinoma.
17 . The use of claim 15 for the treatment of metastases after tumor surgery.